ArticleChinese medicine2026
Ziyuglycoside I promotes wound healing via GPR34-mediated activation of group 3 innate lymphoid cells.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSanguisorba officinalis L., a traditional Chinese medicine, has been frequently utilized to promote the healing of burns and scalds. Ziyuglycoside I (ZG-I), a bioactive compound isolated from the roots of S. officinalis L., exhibits significant properties for wrinkle care, antioxidant activity, and antiviral effects. This study aims to explore the underlying mechanisms by which ZG-I promotes wound healing.
methodsThe efficacy of the treatment was evaluated by monitoring wound closure rates and conducting histological analyses to assess inflammation and re-epithelialization. Immunohistochemistry, utilizing Ki67, α-SMA, and Vimentin antibodies, further characterized the epidermal and dermal repair processes. In vitro, Group 3 innate lymphoid cells (ILC3s) were co-cultured with primary mouse skin fibroblasts, and their proliferation and migration were assessed. The expression of GPR34, secretion of IL-22, and downstream pathways were evaluated. The mechanism was confirmed by knocking down GPR34 in ILC3s. Finally, molecular docking studies, CETSA, and MST experiments validated the interaction between ZG-I and GPR34.
resultsZG-I significantly accelerated wound closure in vivo, accompanied by reduced inflammation and immune cell infiltration, enhanced re-epithelialization, and improved collagen fiber organization. Mechanistically, ZG-I upregulated the expression of GPR34 in ILC3s within the wound tissues and elevated the secretion of IL-22. Furthermore, ZG-I dose-dependently enhanced fibroblast viability, proliferation, and migration, while promoting GPR34 and IL-22 expression in ILC3s in vitro. The knockdown of GPR34 in ILC3s reversed these effects and inhibited downstream signaling pathways, including STAT3, AKT, and MAPK. These results establish that ZG-I promotes wound healing by activating GPR34 in ILC3s, which triggers the AKT and MAPK pathways to enhance STAT3 phosphorylation and IL-22 production.
conclusionOur results indicate that ZG-I has the activity of promoting wound healing, and GPR34 can serve as a therapeutic target for ZG-I in the treatment of skin injury-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.